Shuttle Pharmaceuticals (NASDAQ:SHPH) is dedicated to advancing cancer treatments through its engaging in research, development, and commercialization of innovative therapies. Their operations focus on utilizing radiation enhancers designed to improve the outcomes of radiotherapy in cancer patients, targeting both effectiveness and reduction of side effects. Shuttle Pharmaceuticals works on several projects aimed at personalizing treatment for cancer patients, including the development of novel drugs and the exploration of genetic markers to predict patient response to therapies. Their ultimate objective is to transform cancer treatment by making it more efficient, personalized, and accessible to patients worldwide.